Label: THIDEXAVET- thiabendazole, dexamethasone, neomycin sulfate solution
- NDC Code(s): 17033-207-56, 17033-207-76
- Packager: Dechra Veterinary Products
- Category: PRESCRIPTION ANIMAL DRUG LABEL
- DEA Schedule: None
- Marketing Status: Abbreviated New Animal Drug Application
Updated June 21, 2018
If you are a consumer or patient please visit this version.
- WARNINGS AND PRECAUTIONS
Dermatologic Solution ThiDexaVet Solution contains the following active ingredients per mL: 40 mg thiabendazole, 1 mg dexamethasone, 3.2 mg neomycin (from neomycin sulfate). Inactive ingredients: glycerin, propylene glycol, purifed water, hypophosphorous acid, calcium hypophosphite; about 8.5% ethyl alcohol and about 0.5% benzyl alcohol.
INDICATIONS & USAGE
Dermatologic Solution ThiDexaVet Solution is indicated as an aid in the treatment of certain bacterial, mycotic, and inflammatory dermatoses and otitis externa in dogs and cats. Both acute and chronic forms of these skin disorders respond to treatment with ThiDexaVet Solution. Many forms of dermatosis are caused by bacteria (chiefly Staphylococcus aureus, Proteus vulgaris and Pseudomonas aeruginosa). Moreover, these organisms often act as opportunistic or concurrent pathogens that may complicate already established mycotic skin disorders, or otoacariasis caused by Otodectes cynotis. The principal etiologic agents of dermatomycoses in dogs and cats are species of the genera Microsporum and Trichophyton. The efficacy of neomycin as an antibacterial agent, with activity against both gram-negative and gram-positive pathogens, is well documented. Detailed studies in various laboratories have verified the significant activity thiabendazole displays against the important dermatophytes. Dexamethasone, a synthetic adrenocorticoid steroid, inhibits the reaction of connective tissue to injury and suppresses the classic inflammatory manifestations of skin disease. The formulation for ThiDexaVet Solution combines these several activities in a complementary form for control of the discomfort and direct treatment of dermatitis and otitis externa produced by the above-mentioned infectious agents.
DOSAGE & ADMINISTRATION
DOSAGE AND ADMINISTRATION:
Prior to the administration of Dermatologic Solution ThiDexaVet Solution, remove the ceruminous, purulent or foreign materials from the ear canal, as well as the crust which may be associated with dermatoses affecting other parts of the body.
The design of the container nozzle safely allows partial insertion into the ear canal for ease of administration. The amount to apply and the frequency of treatment are dependent upon the severity and extent of the lesions. Five to 15 drops should be instilled in the ear twice daily. In treating dermatoses affecting other than the ear, the surface of the lesions should be well moistened (2 to 4 drops per square inch) with Dermatologic Solution ThiDexaVet Solution twice daily. The volume required will be dependent upon the size of the lesion. Application of ThiDexaVet Solution should be limited to a period of not longer than one week.
WARNINGS AND PRECAUTIONS
On rare occasions dogs may be sensitive to neomycin. In these animals, application of the drug will result in erythema of the treated area, which may last 24 to 48 hours. Also, evidence of transient discomfort has been noted in some dogs when the drug was applied to fissured or denuded areas. The expression of pain may last 2 to 5 minutes. Application of Dermatologic Solution ThiDexaVet Solution should be limited to periods not longer than one week.
While systemic side effects are not likely with topically applied corticosteroids, such a possibility should be considered if use of the solution is extensive and prolonged. If signs of salt and water retention or potassium excretion are noticed (increased thirst, weakness, lethargy, oliguria, gastrointestinal disturbances or tachycardia), treatment should be discontinued and appropriate measures taken to correct the electrolyte and fluid imbalance.
For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS, or http://www.fda.gov/AnimalVeterinary/SafetyHealth.
Store in a refrigerator 36-46°F (2-8°C).
For topical use in dogs and cats. Avoid contact with eyes.
Keep this and all drugs out of the reach of children.
The Material Safety Data Sheet (MSDS) contains more detailed occupational safety information. To report adverse effects in users, to obtain an MSDS, or for assistance call (866) 933-2472.
- HOW SUPPLIED
- SPL UNCLASSIFIED SECTION
- PRINCIPAL DISPLAY PANEL - 7.5 mL Bottle Carton
- PRINCIPAL DISPLAY PANEL - 15 mL Bottle Carton
INGREDIENTS AND APPEARANCE
thiabendazole, dexamethasone, neomycin sulfate solution
Product Information Product Type PRESCRIPTION ANIMAL DRUG Item Code (Source) NDC:17033-207 Route of Administration AURICULAR (OTIC) Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength THIABENDAZOLE (UNII: N1Q45E87DT) (THIABENDAZOLE - UNII:N1Q45E87DT) THIABENDAZOLE 40 mg in 1 mL DEXAMETHASONE (UNII: 7S5I7G3JQL) (DEXAMETHASONE - UNII:7S5I7G3JQL) DEXAMETHASONE 1 mg in 1 mL NEOMYCIN SULFATE (UNII: 057Y626693) (NEOMYCIN - UNII:I16QD7X297) NEOMYCIN 3.2 mg in 1 mL Inactive Ingredients Ingredient Name Strength GLYCERIN (UNII: PDC6A3C0OX) PROPYLENE GLYCOL (UNII: 6DC9Q167V3) WATER (UNII: 059QF0KO0R) HYPOPHOSPHOROUS ACID (UNII: 8B1RL9B4ZJ) CALCIUM HYPOPHOSPHITE (UNII: CUI83R2732) ALCOHOL (UNII: 3K9958V90M) BENZYL ALCOHOL (UNII: LKG8494WBH) Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:17033-207-76 6 in 1 CARTON 1 7.5 mL in 1 BOTTLE 2 NDC:17033-207-56 6 in 1 CARTON 2 15 mL in 1 BOTTLE Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANADA ANADA200565 12/01/2016 Labeler - Dechra Veterinary Products (362142734)